Universal Flu Vaccine Enters Final Clinical Trials with Promising Results

A universal flu vaccine that could eliminate the need for annual flu shots has entered final-stage clinical trials after showing 95% efficacy against all known influenza strains in Phase 2 testing.

The vaccine works by targeting a part of the flu virus that remains constant across all strains, rather than the rapidly mutating surface proteins targeted by current vaccines. This approach could provide lifelong protection from a single dose.

"This is the holy grail of influenza research," said the lead investigator. "If the Phase 3 results hold, we could see the end of seasonal flu epidemics as we know them."

The Phase 3 trial involves 30,000 participants across 15 countries and is expected to deliver results within 12 months. If successful, the vaccine could receive emergency authorization by early next year.

The development has been welcomed by the World Health Organization, which estimates that seasonal flu causes up to 650,000 deaths worldwide each year. The vaccine could save countless lives, particularly among vulnerable populations including the elderly and immunocompromised.